Similar articles

• New therapies for castration-resistant prostate cancer: efficacy and safety.

  Beltran H, Beer TM, Carducci MA, de Bono J, Gleave M, Hussain M, Kelly WK, Saad F, Sternberg C, Tagawa ST, Tannock IF. Beltran H, et al. Eur Urol. 2011 Aug;60(2):279-90. doi: 10.1016/j.eururo.2011.04.038. Epub 2011 May 4. Eur Urol. 2011. PMID: 21592649 Review.
• Re: Michael J. Morris, Daisy Huang, William K. Kelly, et al. Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate. Eur Urol 2009;56:237-44.

  Drewa T, Chlosta P. Drewa T, et al. Eur Urol. 2010 Feb;57(2):e18-9; author reply e20. doi: 10.1016/j.eururo.2009.10.021. Epub 2009 Oct 20. Eur Urol. 2010. PMID: 19853990 No abstract available.
• Re: Gregory R. Pond, Andrew J. Armstrong, Brian A. Wood, et al. Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer. Eur Urol 2012;61:363-9.

  Shen Y, Ye D. Shen Y, et al. Eur Urol. 2012 Feb;61(2):e3; author reply e4-5. doi: 10.1016/j.eururo.2011.07.056. Epub 2011 Aug 3. Eur Urol. 2012. PMID: 21824719 No abstract available.
• Re: Daniel E. Spratt, Chi Zhang, Zachary S. Zumsteg, Xin Pei, Zhigang Zhang, Michael J. Zelefsky. Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality. Eur Urol 2013;63:709-16.

  Bensimon L, Suissa S, Azoulay L. Bensimon L, et al. Eur Urol. 2013 Aug;64(2):e28. doi: 10.1016/j.eururo.2013.04.014. Epub 2013 Apr 18. Eur Urol. 2013. PMID: 23619391 No abstract available.
• Novel chemotherapies in development for management of castration-resistant prostate cancer.

  Tewari AK, George DJ. Tewari AK, et al. Curr Opin Urol. 2013 May;23(3):220-9. doi: 10.1097/MOU.0b013e32835f7da2. Curr Opin Urol. 2013. PMID: 23511791 Review.